Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

GenScript is delighted to announce its 4th Annual Virtual Summit on Gene and Cell Engineering. This event will feature leading experts from academia, pharma, and biotech, showcasing the transformative ...

Portal Biotechnologies and Multiply Labs announced a collaboration with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.